Polypharmacy and cost analysis in patients suffering from type 2 diabetes mellitus with associated comorbidities

Authors

  • Snehal R. Dhongdi NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, India
  • Riyaz A. Siddiqui Department of Pharmacology, NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20202184

Keywords:

Comorbidities, Diabetes mellitus, Indian national rupee

Abstract

Background: Diabetes mellitus is a common health problem worldwide, associated with several co-morbidities. It requires longer therapy, and is crippling in terms of cost management. The objective of this study was to evaluate co-morbidities in patients suffering from type 2 diabetes and concomitant medications used along with antidiabetic drugs, also analyzing individually cost of drug therapy.

Methods: It is an observational, cross sectional study. The study was conducted at outpatient department, Medicine at a tertiary care hospital. Prescriptions of patients attending the clinic, suffering from type 2 diabetes were analyzed for antidiabetic drugs and other concomitant medications for associated co-morbidities. Their age, sex, number of medications and their costs were noted.

Results: Out of 60 patients evaluated, 36 (60%) were males and 24 (40%) were females. Hypertension in 54 (90%) of the patients and hyperlipidaemia in 23 (38.33%) are the important comorbidities. Metformin was most commonly prescribed antidiabetic drug in this study in 41 (68%), followed by glimepiride 18 (30%), tenegliptin 10 (16.67%), voglibose in 6 (10%) and others. Mean cost of drug therapy to a person was INR 1408.8 per month and INR 16905.6 per annum.

Conclusions: Hypertension 54 (90%) and hyperlipidaemia 23 (38.33%) were the most common associated comorbidities. Metformin and glimepiride were the most common antidiabetic drugs used. Antihypertensive and hypolipidemics were commonly prescribed concomitant medications. Mean cost of drug therapy per person was INR 1408.8 per month and INR 16905.6 per annum.

References

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014;37(Suppl 1):S81-90.

Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Austr Medi J. 2014;7(1):45-8.

Purohit P. A cross-sectional study of type-2 diabetic females at a higher CVD risk owing to a strong correlation of Systolic hypertension to CVD risk factors. Int J Biol Med Res. 2012;3(3):1905-9.

Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross-sectional study at a tertiary care teaching hospital. J Basic Clini Pharm. 2013;4(4):82-7.

Swamy PN, Rao VR. Pharmacoepidemiological and economic evaluation of diabetes mellitus patients with comorbidities, Eur J Pharmaceut Medi Res. 2017;4(9):812-9.

Indu R, Adhikari A, Maisnam I, Basak P, Sur TK, Das AK. Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: An observational and questionnaire-based study. Perspectiv Clini Res. 2018;9(3):139-44.

Upadhyay DK, Palaian S, Ravi Shankar P, Mishra P, Sah AK. Prescribing pattern in diabetic outpatients in a tertiary care teaching hospital in Nepal. J Clin Diagn

Nuthakki S, Pendyala S, Vallabhu C, Kilaru N, Challa SR, Pingili R. An Assessment of Anti-hyperglycemic Drug Utilization Patterns and Adherence to AACE/ACE 2015 Guidelines in South Indian Tertiary Care Teaching Hospital. Ind J Pharm Pract. 2016;9(4):225.

Jelinek HF, Osman WM, Khandoker AH, Khalaf K, Lee S, Almahmeed W, et al. Clinical profiles, comorbidities and complications of type 2 diabetes mellitus in patients from United Arab Emirates. BMJ Open Diab Res Care. 2017;5(1):e000427.

Mandal S, Maiti T, Das AK, Das A, Mandal A, Sarkar BS, et al. Drug utilization study in patients with type 2 diabetes mellitus attending diabetes clinic of a tertiary care hospital in rural Bengal. Int J Basic Clin Pharmacol. 2016;5(4):1647-54.

Adhikari A, Indu R, Bhowal T, Sur TK, Das AK, Chakraborty P. Evaluation of adverse effects due to antidiabetic and cardiovascular drugs in a tertiary care hospital in Kolkata, West Bengal, India. Int J Pharmaceut Sci Res. 2016;7(7):3101.

Singla R, Bindra J, Singla A, Gupta Y, Kalra S. Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice. Ind J Endocrinol Metab. 2019;23(1):40-5.

Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioall Sci. 2016;8(3):223-8.

Pankaj CK, Satendra SP, Dhananjay P, Kumud R, Rajmangal C, Bhanu P. A prospective study on drug utilization pattern of anti-diabetic drugs in a tertiary care teaching hospital of eastern Uttar Pradesh, India. Int J Res Medi Sci. 2019;7(3):669-75.

Swain SP, Samal S, Sahu KS, Rout SK. Out-of-pocket expenditure and drug adherence of patients with diabetes in Odisha. J Family Medi Primary Care. 2018;7(6):1229-35.

Acharya LD, Rau NR, Udupa N, Rajan MS, Vijayanarayana K. Assessment of cost of illness for diabetic patients in South Indian tertiary care hospital. J Pharm Bioal Sci. 2016;8(4):314-20.

Downloads

Published

2020-05-21

How to Cite

Dhongdi, S. R., & Siddiqui, R. A. (2020). Polypharmacy and cost analysis in patients suffering from type 2 diabetes mellitus with associated comorbidities. International Journal of Basic & Clinical Pharmacology, 9(6), 929–933. https://doi.org/10.18203/2319-2003.ijbcp20202184

Issue

Section

Original Research Articles